Simcere to pocket potential $507 million in Almirall deal

29 September 2022

Spanish dermatology specialist Almirall (BME: ALM) and Simcere Pharmaceutical Group (2096: HK) have signed an exclusive licensing agreement for the Chinese firm’s interleukin (IL)-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278.

Under the agreement, Almirall will be granted an exclusive right to develop and commercialize SIM0278 for all indications outside of the Greater China region comprising the Chinese mainland, Hong Kong, Macau and Taiwan.

"This partnership also marks a milestone for Simcere’s globalization effort"Within China, Simcere will retain all rights to develop and commercialize SIM0278, an investigational new drug (IND)-ready subcutaneous injection that will potentially be developed to treat various autoimmune diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK